It turned out that the drug has 100 percent effectiveness, but with a severe form of the disease. In other cases, the efficacy of the coronavirus vaccine was 94.1%.
The study involved more than 30 thousand people, most of whom underwent vaccination without noticeable consequences for the body. "We hope that the vaccine will be a new powerful tool that will change the course of the COVID-19 pandemic," Moderna said in a statement.
Efficacy was independent of the sex, color, and race of the study participant. The control group at the final stage of the trial was attended by 196 people, 33 of whom were over 65 years old.
Moderna representatives are ready to send the vaccine mRNA-1273 for approval to the US Food and Drug Administration and the European Medicines Agency.
A few days ago, the European Commission agreed on a contract with an American company for the supply of 160 million doses of vaccines against the coronavirus. Initially, it is planned to deliver 80 million doses, then another 80 million, if the effectiveness and safety of the drug are proven.
Photo: from open sources